Magnesium L-Threonate (MgT) for Alzheimer's Disease
Also known as: MgT, Magtein, MMFS-01
MgT uniquely crosses the BBB to elevate brain magnesium, enhancing synaptic plasticity and reducing Alzheimer's pathology.
Mechanism of Action
MgT increases brain Mg²⁺ concentration, enhancing NMDA receptor function for long-term potentiation (learning/memory). It reduces calcineurin activity, preserving CREB signaling, and downregulates β-secretase (BACE1) to reduce amyloid production. Elevated brain Mg²⁺ also increases synaptic density.
General mechanism: BBB-penetrant magnesium salt. Elevates brain Mg²⁺ for NMDA receptor modulation, synaptic density enhancement, BACE1 suppression.
Current Evidence
MIT-developed. Phase II trials show improved composite memory scores in older adults with MCI. Animal models show reversal of AD-like cognitive deficits and synaptic loss.
Clinical Status: Phase II positive for MCI. Available as supplement. AD-specific trials planned.
Safety Profile
Very safe. Mild GI effects. No significant interactions. Well-tolerated at recommended doses.
Key Research Questions
- Can MgT slow conversion from MCI to AD dementia?
- Does MgT reduce BACE1 activity in human subjects?